2021 Deal-Making Snapshot
Bolt-On M&A Emphasis Continued In 2021, While Alliance Activity Increased
M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.
You may also be interested in...
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
From a legal family in her native Brazil, Raquel Mura built on her passion for science to work in consumer health care, nutritionals and pharmaceuticals, rising to an R&D leadership position at Sanofi.